VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | The promise of CD123-targeted therapy in BPDCN

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights CD123-targeting agents being explored for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), including tagraxofusp and pivekimab sunirine. Dr Pemmaraju also comments on the potential of CD123-targeted CAR-T therapy and the importance of further investigating this approach. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter